The uncertainty in the market will continue until SEBI comes out with a clarification on October 25, says Gul Tekchandani, investment strategist, on NDTV Profit. This is not the right time to sell but to wait it out for long term gains as the fundamentals are still good for India.
Ranbaxy Laboratories is a good buy at corrections as it has a target price of Rs 530 for a long-term perspective, says a technical analyst on Zee Business. Fresh bookings can be made in this counter with a stop loss of Rs 375, he adds. The stock is currently trading at Rs 417, down 0.95% on the BSE.
No comments:
Post a Comment